Should a urinalysis be obtained for a patient taking empagliflozin (Jardiance) who has vaginal irritation and urinary symptoms?

Yes, obtain a urinalysis for vaginal irritation and urinary symptoms in patients on Jardiance (empagliflozin)

While genital mycotic infections are a well-recognized side effect of SGLT2 inhibitors like Jardiance, you should obtain a urinalysis to rule out urinary tract infection, especially when urinary symptoms are present alongside vaginal irritation. This approach allows you to differentiate between simple genital candidiasis (which is common and typically benign) and a potentially more serious UTI that may require different management.

Clinical Reasoning

Why UA is Warranted

The mechanism of SGLT2 inhibitors creates an environment conducive to both genital and urinary infections by increasing urinary glucose excretion. While genital mycotic infections occur in approximately 5-6% of patients taking empagliflozin 1, the distinction between isolated genital infection and concurrent UTI has important treatment implications.

Key considerations:

• Genital infections with SGLT2 inhibitors are typically mild to moderate and easily treated with topical antifungals 1
• UTI incidence with empagliflozin is similar to placebo (9.4-11.3 per 100 patient-years) 2, but when present requires different management
• Urinary symptoms (dysuria, frequency, urgency) suggest possible UTI rather than isolated genital candidiasis 3, 4

Diagnostic Approach

Obtain urinalysis when:

• Patient reports urinary symptoms (dysuria, frequency, urgency) in addition to vaginal irritation
• Vaginal symptoms are severe or atypical
• Patient has fever or systemic symptoms
• Symptoms persist despite initial treatment for presumed candidiasis

The UA helps you:

• Rule out UTI requiring antibiotics
• Assess for pyuria (though remember pyuria has low positive predictive value for infection) 5
• Guide appropriate treatment decisions

Management Algorithm

If UA Shows No Evidence of UTI:

1. Treat as genital mycotic infection with single-dose fluconazole 150 mg orally 3
2. Counsel on genital hygiene measures 1
3. Continue empagliflozin - most genital infections are mild and do not require drug discontinuation 1
4. Consider topical antifungal if patient prefers or has contraindications to oral therapy

If UA Suggests UTI:

1. Obtain urine culture for complicated cases or recurrent infections 5, 6
2. Treat UTI with appropriate antibiotics based on local resistance patterns
3. Continue empagliflozin unless patient develops severe infection requiring hospitalization (rare: 0.2-0.3% of patients) 2
4. Reassess after treatment completion

If Both Conditions Present:

• Treat both the UTI and genital infection concurrently
• The presence of both does not necessarily require stopping empagliflozin

Important Caveats

Do not automatically discontinue empagliflozin for uncomplicated genital or urinary infections. The cardiovascular and renal benefits of this medication typically outweigh the risk of manageable infections 1.

Risk factors requiring heightened vigilance:

• Uncontrolled hyperglycemia
• Older adults
• Prior history of genitourinary infections
• Uncircumcised males (for genital infections) 7

Red flags requiring immediate evaluation and possible drug discontinuation:

• Signs of Fournier's gangrene (severe perineal pain, fever, tenderness)
• Pyelonephritis symptoms (fever, flank pain, costovertebral angle tenderness)
• Recurrent infections requiring hospitalization

The key is distinguishing between common, manageable side effects and serious infections while maintaining the significant cardiorenal benefits of SGLT2 inhibitor therapy 1.